110 related articles for article (PubMed ID: 1494071)
21. Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals.
Ladabaum U; Mannalithara A; Jandorf L; Itzkowitz SH
Cancer; 2015 Apr; 121(7):1088-97. PubMed ID: 25492455
[TBL] [Abstract][Full Text] [Related]
22. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of faecal occult blood screening for colorectal cancer: results of the Nottingham trial.
Whynes DK
Crit Rev Oncol Hematol; 1999 Nov; 32(2):155-65. PubMed ID: 10612015
[No Abstract] [Full Text] [Related]
24. Cost-effective screening strategies for colorectal cancer.
Whynes DK; Walker AR; Hardcastle JD
J Public Health Med; 1992 Mar; 14(1):43-9. PubMed ID: 1599742
[TBL] [Abstract][Full Text] [Related]
25. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer.
Redaelli A; Cranor CW; Okano GJ; Reese PR
Pharmacoeconomics; 2003; 21(17):1213-38. PubMed ID: 14986736
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model.
Arrospide A; Idigoras I; Mar J; de Koning H; van der Meulen M; Soto-Gordoa M; Martinez-Llorente JM; Portillo I; Arana-Arri E; Ibarrondo O; Lansdorp-Vogelaar I
BMC Cancer; 2018 Apr; 18(1):464. PubMed ID: 29695234
[TBL] [Abstract][Full Text] [Related]
27. Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant.
Wong G; Li MW; Howard K; Hua DK; Chapman JR; Bourke M; Turner R; Tong A; Craig JC
Nephrol Dial Transplant; 2013 Apr; 28(4):917-26. PubMed ID: 23182812
[TBL] [Abstract][Full Text] [Related]
28. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
[TBL] [Abstract][Full Text] [Related]
29. Modelling future capacity needs and spending on colonoscopy in the English bowel cancer screening programme.
Nnoaham KE; Lines C
Gut; 2008 Sep; 57(9):1238-45. PubMed ID: 18441004
[TBL] [Abstract][Full Text] [Related]
30. Cutting cost and increasing access to colorectal cancer screening: another approach to following the guidelines.
Fisher JA; Fikry C; Troxel AB
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):108-13. PubMed ID: 16434595
[TBL] [Abstract][Full Text] [Related]
31. Predicting the impact of the screening programme for colorectal cancer in the UK.
Parkin DM; Tappenden P; Olsen AH; Patnick J; Sasieni P
J Med Screen; 2008; 15(4):163-74. PubMed ID: 19106256
[TBL] [Abstract][Full Text] [Related]
32. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom.
UK Colorectal Cancer Screening Pilot Group
BMJ; 2004 Jul; 329(7458):133. PubMed ID: 15237087
[TBL] [Abstract][Full Text] [Related]
33. Cost analysis in a population based screening programme for colorectal cancer: comparison of immunochemical and guaiac faecal occult blood testing.
Castiglione G; Zappa M; Grazzini G; Sani C; Mazzotta A; Mantellini P; Ciatto S
J Med Screen; 1997; 4(3):142-6. PubMed ID: 9368871
[TBL] [Abstract][Full Text] [Related]
34. Early detection of colorectal cancer with faecal occult blood test screening.
Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H
Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
[TBL] [Abstract][Full Text] [Related]
36. Screening and the costs of treating colorectal cancer.
Whynes DK; Walker AR; Chamberlain JO; Hardcastle JD
Br J Cancer; 1993 Nov; 68(5):965-8. PubMed ID: 8217610
[TBL] [Abstract][Full Text] [Related]
37. The costs of mammography screening in New Zealand: evidence from the pilot programmes.
Menon A; Devlin NJ; Richardson AK
N Z Med J; 1994 Dec; 107(991):501-3. PubMed ID: 7830979
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
39. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
Ladabaum U; Mannalithara A
Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
